Experienced in Metastatic Brain Tumor

Dr. Michael K. Cohenuram

Hematology Oncology | Hematology | Oncology
Yale University
5520 Park Ave, 
Trumbull, CT 
Offers Telehealth
Experienced in Metastatic Brain Tumor
Yale University
5520 Park Ave, 
Trumbull, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Cohenuram is a Hematologist Oncology specialist and a Hematologist in Trumbull, Connecticut. Dr. Cohenuram is rated as an Experienced provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC).

His clinical research consists of co-authoring 1 peer reviewed article and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Metastatic Brain Tumor.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Bridgeport Hospital
Griffin Hospital
Greenwich Hospital Association -
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Chinese Community Health
  • HMO
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

YALE UNIVERSITY
5520 Park Ave, Trumbull, CT 06611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
Journal: Clinical lung cancer
Published: April 20, 2021
Similar Doctors
Elite in Metastatic Brain Tumor
Dr. Jeffrey I. Zwicker
Hematology | Oncology | Hematology Oncology
Elite in Metastatic Brain Tumor
Dr. Jeffrey I. Zwicker
Hematology | Oncology | Hematology Oncology

Memorial Hematology Lymphoma Group

1275 York Ave, 
New York, NY 
 (49.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Zwicker is a Hematologist and an Oncologist in New York, New York. Dr. Zwicker is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Venous Thromboembolism (VTE), Metastatic Brain Tumor, Polycythemia Vera, Thrombocytopenia, and Bone Marrow Aspiration.

Distinguished in Metastatic Brain Tumor
Dr. Harriet Kluger
Hematology | Oncology
Distinguished in Metastatic Brain Tumor
Dr. Harriet Kluger
Hematology | Oncology

Yale University

20 York St, 
New Haven, CT 
 (16.8 miles away)
203-688-4242
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Harriet Kluger is a Hematologist and an Oncologist in New Haven, Connecticut. Dr. Kluger is rated as an Elite provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma (RCC), Melanoma of the Eye, and Nephrectomy.

Distinguished in Metastatic Brain Tumor
Dr. Lyndon J. Kim
Neurosurgery | Oncology | Hematology Oncology
Distinguished in Metastatic Brain Tumor
Dr. Lyndon J. Kim
Neurosurgery | Oncology | Hematology Oncology

Icahn School Of Medicine At Mount Sinai

1 Gustave Levy Place, Mount Sinai Emergency Room, 
New York, NY 
 (47.8 miles away)
212-241-4572
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lyndon Kim is a Neurosurgery specialist and an Oncologist in New York, New York. Dr. Kim is rated as an Elite provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cohenuram's expertise for a condition
ConditionClose
    View All 17 Distinguished Conditions
    View All 12 Advanced Conditions
    View All 91 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile